Our team is headed to San Diego for AACR in less than two weeks! We’re excited to show how Synoligo supports the cancer research community with high‑quality, customizable oligonucleotide solutions, from discovery through translational research. We look forward to connecting with researchers who are advancing oncology science and exploring how we can support their work. […]
Read more »
We’re excited to be a proud sponsor of the CRISPR Medicine Conference in Copenhagen this year. Our team looks forward to connecting around the breakthroughs and challenges shaping the gene editing space. At Synoligo, we provide high‑quality gRNA synthesis across flexible scales, from discovery to high‑throughput plate formats, enabling teams to scale CRISPR programs efficiently […]
Counting down to OPT Congress 2026 in Boston! With four focused conference tracks and pre‑conference short courses, OPT Congress offers deep scientific insight into RNA therapeutics, oligonucleotides, peptides, and next‑generation conjugates—all in one place. At Synoligo, we’re excited to contribute to those conversations by bringing what matters most to advancing your programs: 🔬 Custom oligo […]
We are proud to partner with the 7th RNAi-Based Therapeutics Summit (January 27th-29th, Boston MA)! The definitive industry focused forum to discover, develop & selectively deliver highly stable & potent RNAi therapeutics for targeted & effective gene silencing in oncology, rare, cardiovascular disorders & beyond. Will you be joining us there?
🎉 And the show goes on! Synoligo is wrapping up the year strong with our final event, AMP 2025! 📍 Find us at Booth #123 to discuss your next custom probe project and explore how our synthesis capabilities can support your diagnostics and research goals. 🧪 Prefer to shop online? Visit our website to browse […]
It’s been fantastic reconnecting with familiar faces from OTS and meeting new connections during the first two days at #TIDESEurope! If you’re attending and looking for a one-stop oligo solution, visit us at Booth#318 to learn how we can advance your pipeline from discovery to pre-clinical stage. Ask about our first-time customer incentive program for […]
That’s a wrap on an incredible week at OTS2025 in Budapest! The event was filled with inspiring talks and meaningful conversations that left us energized about the future of oligonucleotide therapeutics. Next stop: San Diego for the 16th World ADC in two weeks! Synoligo is proud to be among the select few companies, out of […]
As a sponsor of the 21st Annual Meeting of the Oligonucleotide Therapeutics Society, Synoligo is eager to engage with the researchers and experts who are shaping the future of oligo therapeutics, including those working on antisense, siRNA, immunostimulatory, and aptamers. Stop by Booth#27 to learn how our services are designed to accelerate your process and […]
We are heading back to Boston! The Synoligo team is excited to exhibit at the American Society of Human Genetics Annual Meeting next month. We are bringing our advanced oligo synthesis capabilities to diagnostic companies looking for a quality partner. Meet our BD Director, Marc Beal, at Booth#560 to discuss your project. Plus, take advantage […]
The RNA Leaders USA Congress continues to grow each year, and Synoligo is proud to support its expansion as a sponsor in 2025. Our team will be on site to connect, exchange insights, and explore emerging innovations in the RNA space. We hope to meet you at our booth#23! Check out our therapeutic oligos page: […]
Synoligo is at the 5th Oligonucleotides for CNS Summit! As experts in synthesizing custom ASOs, siRNAs, miRNAs, and saRNAs, we are ready to contribute our knowledge and expertise to help optimize delivery and reduce toxicity for oligos treating CNS diseases. Connect with us to discuss how we can help with your current or future project! […]
The 4th Oligonucleotides Analytical Development and CMC Summit is happening now, and our team is there! We’re diving deep into the conversations that matter, tackling the unique challenges in oligo analytical development and CMC scale-up. At Synoligo, we know flexibility is key to your success. Whether you need tubes for a single experiment or plates […]
Synoligo Biotechnologies Launches Cutting-Edge E-commerce Platform for Oligonucleotide Synthesis, Empowering Researchers with Streamlined Access Morrisville, North Carolina – July 23, 2025 – Synoligo Biotechnologies Inc., a leader in custom oligonucleotide synthesis, has announced the launch of its new e-commerce website, transforming the way researchers access high-quality oligonucleotides. The platform addresses critical needs in the scientific […]
The 6th RNA Editing Summit is just around the corner, and Synoligo is excited to sponsor this premier gathering of scientific leaders and innovators. From breakthrough editing technologies to strategies for advancing programs toward the clinic, the summit will also unveil never-before-seen clinical data that could shape the next wave of therapeutic innovation. Mark your […]
The RNA Therapeutics: From Concept to Clinic Conference was a tremendous success last year, and we are thrilled to return as a sponsor. This year’s symposium promises another opportunity to bring together scientists, clinicians, and innovators from across sectors. Synoligo looks forward to engaging with attendees and offering our expertise in custom oligonucleotide synthesis.
As a sponsor of the 4th Dutch Antisense Therapeutics Symposium, Synoligo reaffirms its commitment to advancing oligonucleotide innovation. Representing us at the symposium, Dr. John Randolph will engage with fellow experts to explore emerging strategies and share how Synoligo’s manufacturing capabilities can support cutting-edge research across the Netherlands.
SynOligo Biotechnologies and Lumiphore Announce a Partnership to Provide [Time-Resolved] Luminescent Oligos and Assays for the Nucleic Acid Amplification Testing Market (NAAT) The partnership aims to provide game-changing luminescent lanthanide-based oligo probes for diagnostics and life science research applications. Morrisville, NC / Berkeley, CA, May 19th, 2025. SynOligo Biotechnologies Inc. and Lumiphore Inc. announced they […]
The RNA Society is celebrating its 30th Annual Meeting in San Diego, and we are excited to be part of it as an exhibitor! Dr. John Randolph will be representing Synoligo and connecting with the RNA research community to share our oligonucleotide manufacturing capabilities. We look forward to seeing you there!
Synoligo is proud to support TIDES USA, one of North America’s premier conferences for oligonucleotide and peptide therapeutics. This event aligns with our core belief in the power of collaboration and knowledge sharing to drive innovation, from early discovery to clinical application. Visit us at booth #313!
Synoligo is committed to staying at the forefront of RNA innovation. That’s why we’re proud to sponsor the 4th Circular & saRNA Therapeutics Summit. Events like this are vital for sharing ideas and driving forward the next generation of RNA therapeutics. Mark your calendar!
Synoligo is excited to announce our sponsorship of the 4th Annual Novel Conjugates Summit next month. Our team is prepared to engage with industry experts and showcase how our oligo conjugation services can help drive innovation in targeted cancer therapies. Join us! https://lnkd.in/giCX9Fgn
Synoligo is proud to sponsor the 10th Annual OPT Congress, where innovation in oligonucleotide therapies takes center stage! This year’s program highlights emerging oligo modalities and cutting-edge approaches to designing targeted treatments. We hope to see you there!
This year, we’re back as a sponsor for the RNA Leaders Europe Congress! Our team is eager to connect with researchers and industry leaders spanning the entire RNA spectrum, including oligo-based RNA, next-gen RNA, and mRNA vaccines and therapeutics. Let’s drive RNA innovation together!
Looking ahead to January 2025, Synoligo is proud to sponsor our first event, the 6th Annual RNAi-Based Therapeutics Summit! Our team is eager to connect with leading experts and delve into advancements in chemical modifications for the next-generation.
